Company Profile
PLUS THERAPEUTICS, Inc. Stock Price, News & Analysis
Company overview
Business overview
PLUS THERAPEUTICS is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, PLUS THERAPEUTICS is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
PLUS THERAPEUTICS follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, PLUS THERAPEUTICS sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
PSTV is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
PLUS Therapeutics’s catalysts are Rhenium-based oncology programs and any clinical or regulatory update that keeps the platform moving. The company remains highly dependent on proof of concept.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic
Source: PLUS THERAPEUTICS, Inc.
- 03
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives
Source: PLUS THERAPEUTICS, Inc.
- 04
- 05
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas
Source: PLUS THERAPEUTICS, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.